NKGen Biotech (NKGN) Short Interest Ratio & Short Volume $0.34 -0.03 (-8.80%) As of 06/4/2025 03:59 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NKGen Biotech Short Interest DataNKGen Biotech (NKGN) has a short interest of 135,200 shares. This marks a 349.17% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.2, indicating that it would take 0.2 days of the average trading volume of 1.57 million shares to cover all short positions.Current Short Interest135,200 sharesPrevious Short Interest30,100 sharesChange Vs. Previous Month+349.17%Dollar Volume Sold Short$44,278.00Short Interest Ratio0.2 Days to CoverLast Record DateMay 15, 2025Outstanding Shares44,948,000 sharesPercentage of Shares Shorted0.30%Today's Trading Volume154,247 sharesAverage Trading Volume1,570,670 sharesToday's Volume Vs. Average10% Short Selling NKGen Biotech? Sign up to receive the latest short interest report for NKGen Biotech and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNKGN Short Interest Over TimeNKGN Days to Cover Over TimeNKGN Percentage of Float Shorted Over Time NKGen Biotech Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/2025135,200 shares $44,278.00 +349.2%N/A0.2 $0.33 4/30/202530,100 shares $4,951.45 -65.6%N/A0.2 $0.16 4/15/202587,400 shares $11,379.48 +5.6%N/A0.3 $0.13 3/14/2025243,000 shares $41,261.40 -82.9%N/A0.1 $0.17 2/14/20251,510,000 shares $952,810.00 +189.8%5.4%0.4 $0.63 1/31/2025521,000 shares $254,508.50 -7.2%2.2%1 $0.49 1/15/2025561,300 shares $285,140.40 -20.5%3.0%0.8 $0.51 NKGN Short Interest - Frequently Asked Questions What is NKGen Biotech's current short interest? Short interest is the volume of NKGen Biotech shares that have been sold short but have not yet been closed out or covered. As of May 15th, traders have sold 135,200 shares of NKGN short. Learn More on NKGen Biotech's current short interest. Is NKGen Biotech's short interest increasing or decreasing? NKGen Biotech saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 135,200 shares, an increase of 349.2% from the previous total of 30,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does NKGen Biotech's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to NKGen Biotech: Cue Biopharma, Inc. (1.61%), bluebird bio, Inc. (2.91%), Century Therapeutics, Inc. (6.31%), PepGen Inc. (8.30%), Adverum Biotechnologies, Inc. (11.42%), Mural Oncology plc (4.77%), PMV Pharmaceuticals, Inc. (1.92%), Prelude Therapeutics Incorporated (3.60%), Anebulo Pharmaceuticals, Inc. (0.14%), Quince Therapeutics, Inc. (1.73%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short NKGen Biotech stock? Short selling NKGN is an investing strategy that aims to generate trading profit from NKGen Biotech as its price is falling. NKGN shares are trading down $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NKGen Biotech? A short squeeze for NKGen Biotech occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NKGN, which in turn drives the price of the stock up even further. How often is NKGen Biotech's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NKGN, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies CUE Short Squeeze BLUE Short Squeeze IPSC Short Squeeze PEPG Short Squeeze ADVM Short Squeeze MURA Short Squeeze PMVP Short Squeeze PRLD Short Squeeze ANEB Short Squeeze QNCX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:NKGN) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredBanks aren’t ready for this altcoin—are you?I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.